NCT03112681已完成2 期
A Phase 2, Prospective, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Tolerability and Efficacy of Saroglitazar Magnesium in Patients With Primary Biliary Cholangitis (EPICS )
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 37
- 试验地点
- 9
- 主要终点
- Effect of a 16-week Treatment Regimen of Saroglitazar Magnesium 2 mg and 4 mg on Alkaline Phosphatase (ALP) Levels in Patients With Primary Biliary Cholangitis.
研究概览
简要总结
prospective, multicenter, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability and efficacy of saroglitazar magnesium 2 mg, 4 mg in Patients with Primary Biliary Cholangitis. A total 36 subjects will be enrolled in a ratio of 1:1:1 to receive either saroglitazar magnesium 2 mg or saroglitazar magnesium 4 mg or placebo.
详细描述
Study SARO.16.004.02 is a prospective, multicenter, randomized, double-blind, placebo-controlled study to evaluate safety, tolerability and efficacy of saroglitazar magnesium 2 mg, 4 mg in Patients with Primary Biliary Cholangitis.
A total 36 subjects will be enrolled in a ratio of 1:1:1 to receive either saroglitazar magnesium 2 mg or saroglitazar magnesium 4 mg or placebo. The primary objective is to investigate the effect of a 16-week treatment regimen of Saroglitazar magnesium 2 mg and 4 mg on ALP levels in patients with Primary Biliary Cholangitis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
盲法说明
Double-blind
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males or females, between 18 and 75 years of age, inclusive.
- •a) Patients on therapeutic doses of Ursodeoxycholic acid (UDCA) for ≥12 months and stable therapy for ≥3 months prior to enrolment.
- •OR b) Patients who are unable to tolerate UDCA, and did not receive UDCA for at least 3 months from the date of screening.
- •History of confirmed Primary Biliary Cholangitis Diagnosis, based on American Association for the Study of Liver Disease [AASLD] and European Association for Study of the Liver [EASL] Practice Guidelines; [Lindor 2009; EASL 2009], as demonstrated by the presence of at least≥2 of the following 3 diagnostic factors:
- •History of elevated Alkaline Phosphatase levels for at least 6 months prior to Screening Visit 1
- •Positive antimitochondrial antibodies (AMA) titer or if AMA negative or in low titer (<1:80) PBC specific antibodies (anti-GP210 and/or anti-SP100 and/or antibodies against the major M2 components [PDC-E2, 2-oxo-glutaric acid dehydrogenase complex])
- •Liver biopsy consistent with PBC.
- •ALP ≥1.67x upper limit of normal (ULN) at Visit 1 and Visit 2 and with < 30% variance between the levels from Visit 1 to Visit
- •Contraception: Female patients must be postmenopausal, surgically sterile, or if premenopausal, agree to use ≥ 1 effective method of contraception during the trial. Effective methods of contraception are considered to be Hormonal (e.g., contraceptive pill, patch, intramuscular implant or injection); or Double barrier method, i.e., (a) condom (male or female) or (b) diaphragm, with spermicide; or Intrauterine device (IUD); or Vasectomy (partner).
- •Must provide written informed consent and agree to comply with the trial protocol.
排除标准
- •Consumption of >3 units of alcohol per day (>21 units per week) if male and >2 units of alcohol per day (>14 units per week) if female for at least 3 consecutive months in the last 5 years (Note: 1 unit = 12 ounces of beer, 4 ounces of wine or 1 ounce of spirits/hard liquor).
- •History or presence of other concomitant liver diseases including:
- •Hepatitis B or C virus (HCV, HBV) infection
- •Primary sclerosing cholangitis (PSC)
- •Alcoholic liver disease
- •Definite autoimmune liver disease or overlap syndrome
- •Non-alcoholic steatohepatitis (NASH)
- •Cirrhosis with complications, including history or presence of: spontaneous bacterial peritonitis, hepatocellular carcinoma, bilirubin > 2x ULN, ascites, encephalopathy, known esophageal varices or history of variceal bleeding and active or history of hepatorenal syndrome.
- •History of any venous thromboembolism, TIA, intracranial hemorrhage, neoplasm, arteriovenous malformation, vasculitis, bleeding disorder, coagulation disorders or screening blood tests that indicate altered coagulability (e.g. platelet count, aPTT, PTT or TT tests).
- •Patients with INR > ULN at visit
- •Patients with total bilirubin > ULN at visit 1 that is not due to Gilbert's syndrome
- •Patients with >30% increase in ALT, total bilirubin, or INR between Visit 1 to Visit
- •Patients with serum creatinine >ULN according to the gender at Visit
- •Patients with abnormal total creatine kinase (CK) OR lipase OR amylase at Visit
- •Unstable cardiovascular disease, including:
- •unstable angina, (i.e., new or worsening symptoms of coronary heart disease within the past 3 months), acute coronary syndrome within the past 6 months, acute myocardial infarction in the past 3 months or heart failure of New York Heart Association class (III - IV) or worsening congestive heart failure, or coronary artery intervention, within the past 6 months
- •history of (within prior 3 months) or current unstable cardiac dysrhythmias
- •uncontrolled hypertension (systolic blood pressure [BP] >160 mmHg and/or diastolic BP >100 mmHg)
- •stroke or transient ischemic attack within the prior 6 months
- •History of malignancy in the past 5 years and/or active neoplasm with the exception of resolved superficial nonmelanoma skin cancer.
- •Contraindications to Saroglitazar magnesium or has any conditions affecting the ability to evaluate the effects of Saroglitazar magnesium.
- •Known allergy, sensitivity or intolerance to the study drug, comparator or formulation ingredients.
- •Participation in any other clinical study within the previous 3 months of screening.
- •Illicit substance abuse within the past 6 months.
- •History or other evidence of severe illness or any other conditions that would make the patient, in the opinion of the investigator, unsuitable for the study (such as poorly controlled psychiatric disease, human immunodeficiency virus (HIV), coronary artery disease or active gastrointestinal conditions that might interfere with drug absorption).
研究组 & 干预措施
Saroglitazar magnesium 2 mg
Experimental
Saroglitazar magnesium 2 mg tablet Once daily for 16 weeks
干预措施: Saroglitazar magnesium 2 mg (Drug)
Saroglitazar magnesium 4 mg
Experimental
Saroglitazar magnesium 4 mg tablet Once daily for 16 weeks
干预措施: Saroglitazar magnesium 4 mg (Drug)
Placebo
Placebo Comparator
Placebo tablet Once daily for 16 weeks
干预措施: Placebo Oral Tablet (Drug)
结局指标
主要结局
Effect of a 16-week Treatment Regimen of Saroglitazar Magnesium 2 mg and 4 mg on Alkaline Phosphatase (ALP) Levels in Patients With Primary Biliary Cholangitis.
时间窗: Baseline and Week 16
Change in ALP levels after 16 weeks of Saroglitazar magnesium 2 mg and 4 mg treatment.
次要结局
未报告次要终点
研究者
研究点 (9)
Loading locations...
相似试验
Unknown
2 期
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous AGX-201 for Migraine ProphylaxisMigraine ProphylaxisNCT02021474AgoneX Biopharmaceuticals, Inc.130
已完成
2 期
To Evaluate the Efficacy and Safety of HSK31679 in Chinese Patients With Non-Alcoholic Steatohepatitis (NASH) .Non-Alcoholic Steatohepatitis (NASH)NCT06168383Haisco Pharmaceutical Group Co., Ltd.186
已完成
2 期
NNITS-Nitazoxanide for Norovirus in Transplant Patients StudyGastroenteritis NorovirusNCT03395405National Institute of Allergy and Infectious Diseases (NIAID)31
已完成
2 期
Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa InfectionNon-cystic Fibrosis BronchiectasisPseudomonas AeruginosaLung InfectionNCT05616221Armata Pharmaceuticals, Inc.48
Unknown
2 期
Efficacy and Safety of AD-35 in Treatment of Subjects With Mild to Moderate Alzheimer's DiseaseAlzheimer Disease, Early OnsetNCT03625401Zhejiang Hisun Pharmaceutical Co. Ltd.55